You just read:

Braeburn Pharmaceuticals and Camurus announce Enrollment goals reached in two pivotal Phase 3 Trials of CAM2038 for treatment of opioid dependence

News provided by

Braeburn Pharmaceuticals

Apr 05, 2016, 02:00 ET